Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Acquired by Worldquant Millennium Advisors LLC

Worldquant Millennium Advisors LLC raised its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 43.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,752 shares of the medical research company's stock after purchasing an additional 3,257 shares during the quarter. Worldquant Millennium Advisors LLC's holdings in Bio-Rad Laboratories were worth $3,597,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in BIO. Quadrature Capital Ltd lifted its holdings in Bio-Rad Laboratories by 14.0% during the 3rd quarter. Quadrature Capital Ltd now owns 6,034 shares of the medical research company's stock valued at $2,021,000 after buying an additional 739 shares in the last quarter. Quantinno Capital Management LP bought a new stake in shares of Bio-Rad Laboratories during the third quarter valued at approximately $403,000. Quarry LP raised its stake in shares of Bio-Rad Laboratories by 38.1% during the third quarter. Quarry LP now owns 297 shares of the medical research company's stock valued at $99,000 after acquiring an additional 82 shares in the last quarter. Philosophy Capital Management LLC boosted its holdings in shares of Bio-Rad Laboratories by 4.2% in the third quarter. Philosophy Capital Management LLC now owns 59,147 shares of the medical research company's stock valued at $19,789,000 after purchasing an additional 2,378 shares during the period. Finally, Point72 Asset Management L.P. bought a new position in Bio-Rad Laboratories in the third quarter worth approximately $83,681,000. 65.24% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

BIO has been the subject of a number of research analyst reports. Royal Bank of Canada lifted their target price on Bio-Rad Laboratories from $446.00 to $469.00 and gave the company an "outperform" rating in a research report on Thursday, October 31st. Wells Fargo & Company initiated coverage on Bio-Rad Laboratories in a report on Tuesday, August 27th. They issued an "equal weight" rating and a $340.00 price objective for the company. Citigroup increased their target price on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. Finally, StockNews.com raised shares of Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research report on Friday, November 1st. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Bio-Rad Laboratories has an average rating of "Moderate Buy" and an average price target of $391.80.

Bio-Rad Laboratories Stock Up 1.0 %

Shares of NYSE BIO traded up $3.14 during mid-day trading on Friday, reaching $325.50. 151,252 shares of the company were exchanged, compared to its average volume of 184,972. The firm has a 50-day moving average of $341.22 and a 200 day moving average of $319.21. Bio-Rad Laboratories, Inc. has a 1 year low of $262.12 and a 1 year high of $387.99. The company has a quick ratio of 4.52, a current ratio of 6.14 and a debt-to-equity ratio of 0.16. The stock has a market cap of $9.11 billion, a price-to-earnings ratio of -11.91 and a beta of 0.90.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The medical research company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.16 by $0.85. The business had revenue of $649.70 million during the quarter, compared to analyst estimates of $628.18 million. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The company's quarterly revenue was up 2.8% on a year-over-year basis. During the same period in the prior year, the firm posted $2.33 earnings per share. On average, research analysts expect that Bio-Rad Laboratories, Inc. will post 10.29 earnings per share for the current year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.